Elanco Animal Health (ELAN) director receives 10,314-share annual equity award
Rhea-AI Filing Summary
Elanco Animal Health Inc. director reports equity grant. A non-employee member of Elanco’s Board of Directors reported receiving a grant of 10,314 shares of common stock on 11/28/2025 as an annual equity award, structured as deferred stock units with a stated price of $0 for reporting purposes. Following this award, the director beneficially owns 12,853 shares of Elanco common stock in direct ownership. The transaction was reported on a Form 4 as a routine board compensation grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 10,314 shares
Net Buy
1 txn
Insider
Ma Stacey
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 10,314 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 12,853 shares (Direct)
Footnotes (1)
- F1. Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Elanco Animal Health (ELAN) disclose in this Form 4?
A non-employee director of Elanco Animal Health Inc. (ELAN) reported receiving an annual equity award of 10,314 shares of common stock on 11/28/2025.
What was the nature of the equity award reported by Elanco (ELAN)?
The filing describes the transaction as a grant of deferred stock units given as an annual equity award to each non-employee member of Elanco’s Board of Directors.
Was this Elanco (ELAN) Form 4 transaction a purchase or a grant?
The Form 4 characterizes the event as an acquisition of shares through a grant of deferred stock units, not an open-market purchase.
What transaction code is used for the Elanco (ELAN) director’s equity grant?
The transaction is coded as A, indicating an acquisition of securities, consistent with an equity award grant.